Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.

Macek Jilkova, Zuzana

Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. [electronic resource] - Clinical and translational gastroenterology 07 2019 - e00058 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

2155-384X

10.14309/ctg.0000000000000058 doi


Aged
Antigens, CD--drug effects
CD4-Positive T-Lymphocytes--drug effects
CD8-Positive T-Lymphocytes--drug effects
Carcinoma, Hepatocellular--drug therapy
Disease Progression
Female
Hepatitis A Virus Cellular Receptor 2--drug effects
Humans
Immunotherapy--methods
Liver Neoplasms--pathology
Male
Neoplasm Staging--methods
Predictive Value of Tests
Prognosis
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Protein Kinase Inhibitors--therapeutic use
Sorafenib--therapeutic use
Up-Regulation
Lymphocyte Activation Gene 3 Protein